Minsheng Health announced on September 30 that the company received the Drug Supplementary Application Approval Notice for Glucosamine Sulfate Capsules issued by the National Medical Products Administration. The drug is indicated for primary and secondary osteoarthritis, with the main ingredient being glucosamine sulfate sodium chloride. The specification is 0.25 grams calculated as glucosamine sulfate, or 0.314 grams calculated as glucosamine sulfate sodium chloride. The drug has a shelf life of 18 months, and the approval number is H20255903. In the first half of 2026, Minsheng Health achieved revenue of 535 million yuan and net profit attributable to the parent company of 83.39 million yuan.
Hangzhou Minsheng Healthcare Co LtdMinsheng Health received NMPA approval of its supplementary application for Glucosamine Sulfate Capsules, a regulatory clearance for the drug.
